Literature DB >> 2141358

Normal striatal glucose consumption in two patients with benign hereditary chorea as measured by positron emission tomography.

T Kuwert1, H W Lange, K J Langen, H Herzog, H Hefter, A Aulich, L E Feinendegen.   

Abstract

Positron emission tomography (PET) with [18F]-2-fluoro-2-deoxy-D-glucose (FDG) was used to investigate the regional cerebral metabolic rate of glucose consumption (rCMRGlc) in two patients with benign hereditary chorea (BHC) and 21 normal subjects. Relative and absolute values of cerebellar, striatal, thalamic, and cortical rCMRGlc were within normal limits for both patients with BHC, indicating that the choreic movement disorder encountered in these two patients was not caused by a decrease of energy metabolism in the striatum such as that found regularly in most patients with other forms of chorea (e.g. Huntington's and Wilson's disease).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2141358     DOI: 10.1007/bf00314666

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  Brain glucose utilization in childhood Huntington's disease studied with positron emission tomography (PET).

Authors:  A De Volder; A Bol; C Michel; M Cogneau; P Evrard; G Lyon; A M Goffinet
Journal:  Brain Dev       Date:  1988       Impact factor: 1.961

2.  Hereditary nonprogressive chorea of early onset.

Authors:  A F Haerer; R D Currier; J F Jackson
Journal:  N Engl J Med       Date:  1967-06-01       Impact factor: 91.245

3.  Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.

Authors:  D E Kuhl; E J Metter; W H Riege; C H Markham
Journal:  Ann Neurol       Date:  1984       Impact factor: 10.422

4.  Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509.

Authors:  Alastair Compston
Journal:  Brain       Date:  2009-08       Impact factor: 13.501

5.  Regional cerebral glucose metabolism in SLE chorea: further evidence that striatal hypometabolism is not a correlate of chorea.

Authors:  M Guttman; A E Lang; E S Garnett; C Nahmias; G Firnau; F J Tyndel; A S Gordon
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

6.  Cerebral glucose metabolic rates in normal human females versus normal males.

Authors:  L R Baxter; J C Mazziotta; M E Phelps; C E Selin; B H Guze; L Fairbanks
Journal:  Psychiatry Res       Date:  1987-07       Impact factor: 3.222

7.  The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease.

Authors:  M R Hayden; J Hewitt; A J Stoessl; C Clark; W Ammann; W R Martin
Journal:  Neurology       Date:  1987-09       Impact factor: 9.910

8.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution.

Authors:  K Hamacher; H H Coenen; G Stöcklin
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

9.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.

Authors:  J C Mazziotta; M E Phelps; J J Pahl; S C Huang; L R Baxter; W H Riege; J M Hoffman; D E Kuhl; A B Lanto; J A Wapenski
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

10.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

View more
  1 in total

1.  Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease.

Authors:  T Kuwert; H W Lange; H Boecker; H Titz; H Herzog; A Aulich; B C Wang; U Nayak; L E Feinendegen
Journal:  J Neurol       Date:  1993-11       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.